Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity

European Journal of Immunology

Volumn 44, Issue 4, 2014, Pages 1039-1045

  Catucci, Marco ^a   Zanoni, Ivan ^b   Draghici, Elena ^a   Bosticardo, Marita ^a   Castiello, Maria C ^a,c   Venturini, Massimo ^a   Cesana, Daniela ^a   Montini, Eugenio ^a   Ponzoni, Maurilio ^a   Granucci, Francesca ^b   Villa, Anna ^a,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d CNR   (Italy)

Author keywords

Antitumor immunity; DCs; Immune surveillance; NK cells; Wiskott Aldrich syndrome

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN P 15095; WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; WISKOTT ALDRICH SYNDROME;

ANTITUMOR IMMUNITY; DCS; IMMUNE SURVEILLANCE; NK CELLS; WISKOTT-ALDRICH SYNDROME;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TUMOR BURDEN; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84898006391     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343935     Document Type: Article

References (20)

1. Ochs, H. D. and Thrasher, A. J., The Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. 2006. 117: 725-738.
2. Sullivan, K. E., Mullen, C. A., Blaese, R. M. and Winkelstein, J. A., A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 1994. 125: 876-885.
3. Imai, K., Morio, T., Zhu, Y., Jin, Y., Itoh, S., Kajiwara, M., Yata, J.-I. et al., Clinical course of patients with WASP gene mutations. Blood 2004. 103: 456-464.
4. Kim, R., Emi, M. and Tanabe, K., Cancer immunoediting from immune surveillance to immune escape. Immunology 2007. 121: 1-14.
5. Ishihara, D., Dovas, A., Hernandez, L., Pozzuto, M., Wyckoff, J., Segall, J. E., Condeelis, J. S. et al., Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis. Cell Rep. 2013. 4: 429-436.
6. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D. and DePinho, R. A., Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996. 85: 27-37.
7. Sherr, C. J., Principles of tumor suppression. Cell 2004. 116: 235-246.
8. Takeda, K., Nakayama, M., Sakaki, M., Hayakawa, Y., Imawari, M., Ogasawara, K., Okumura, K. et al., IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J. Leukoc. Biol. 2011. 90: 777-785.
9. Orange, J. S., Ramesh, N., Remold-O'Donnell, E., Sasahara, Y., Koopman, L., Byrne, M., Bonilla, F. A. et al., Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc. Natl. Acad. Sci. USA 2002. 99: 11351-11356.
10. Gismondi, A., Cifaldi, L., Mazza, C., Giliani, S., Parolini, S., Morrone, S., Jacobelli, J. et al., Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 2004. 104: 436-443.
11. Borg, C., Jalil, A., Laderach, D., Maruyama, K., Wakasugi, H., Charrier, S., Ryffel, B. et al., NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004. 104: 3267-3275.
12. Ma, Y., Aymeric, L., Locher, C., Kroemer, G. and Zitvogel, L., The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 2011. 23: 146-152.
13. Zanoni, I., Foti, M., Ricciardi-Castagnoli, P. and Granucci, F., TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells. J. Immunol. 2005. 175: 286-292.
14. Hochweller, K., Striegler, J., Hämmerling, G. J. and Garbi, N., A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur. J. Immunol. 2008. 38: 2776-2783.
15. Terabe, M. and Berzofsky, J. A., The role of NKT cells in tumor immunity. Adv. Cancer Res. 2008. 101: 277-348.
16. Ikeda, H., Chamoto, K., Tsuji, T., Suzuki, Y., Wakita, D., Takeshima, T. and Nishimura, T., The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004. 95: 697-703.
17. Monypenny, J., Chou, H.-C., Bañón-Rodríguez, I., Thrasher, A. J., Antón, I. M., Jones, G. E. and Calle, Y., Role of WASP in cell polarity and podosome dynamics of myeloid cells. Eur. J. Cell Biol. 2011. 90: 198-204.
18. Zhang, J., Shehabeldin, A., da Cruz, L. A., Butler, J., Somani, A. K., McGavin, M., Kozieradzki, I. et al., Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J. Exp. Med. 1999. 190: 1329-1342.
19. Moriya, K., Wakabayashi, A., Shimizu, M., Tamura, H., Dan, K. and Takahashi, H., Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells. Cancer Immunol. Immunother. 2010. 59: 1083-1095.
20. Dupré, L., Marangoni, F., Scaramuzza, S., Trifari, S., Hernández, R. J., Aiuti, A., Naldini, L. et al., Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum. Gene Ther. 2006. 17: 303-313.